

ENDURING MATERIAL LEARNER NOTIFICATION

Total Health Conferencing

Optimizing Therapy in HER2+ Disease Resham Mahtani

Date of CE Release: August 12, 2020

Date of CE Expiration: August 12, 2023

Location: Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

Amedco LLC designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Amedco LLC designates this activity for a maximum of .75 ANCC contact hours.

Pharmacists

Amedco LLC designates this activity for a maximum of .75 knowledge-based CPE contact hours.

UAN(s): JA4008163-9999-20-107-H04-P

NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

Objectives - After Attending This Program You Should Be Able To

1. Review and discuss the available treatment options for this patient population and discuss how we might individualize therapy in the future to optimize the balance of efficacy and toxicity.
2. Review the addition of pertuzumab to a trastuzumab-based adjuvant regimen and discuss improvement of pathologic complete response rates and invasive disease-free survival.
3. Review the addition of neratinib for patients with high-risk disease and discuss improvement disease-in free survival.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First	Last	Commercial Interest
Justin	Kaiser	NA

First	Last	Commercial Interest
Reshma	Mahtani	Genentech:Research Grant Overall Principal Investigator,Agendia, Amgen, Celgene, Esai, Genentech, Lilly, Novartis, Pfizer, Puma:Consultant
Daylin	Miller	NA

How to Get Your Certificate:

1. CME Link: <https://workshop-evaluator.herokuapp.com/evaluation/7508>
2. Evaluate the meeting.
3. Print all pages of your certificate for your records.

Questions about your credit certificate? Email Certificate@AmedcoEmail.com